相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis
Kristian Reich et al.
EXPERIMENTAL DERMATOLOGY (2015)
IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies
Andrew Blauvelt et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Diamant Thaci et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
Ulrich Mrowietz et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Christopher E. M. Griffiths et al.
LANCET (2015)
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
Herve Bachelez et al.
LANCET (2015)
Clinical improvement in psoriasis with specific targeting of interleukin-23
Tamara Kopp et al.
NATURE (2015)
IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases
Michele W. L. Teng et al.
NATURE MEDICINE (2015)
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
Kenneth B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)
C. Paul et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
Iain B. McInnes et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials
J. Schmitt et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
Howard Sofen et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study
Mamitaro Ohtsuki et al.
JOURNAL OF DERMATOLOGY (2014)
Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points
L. Puig et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Secukinumab failure in Crohn's disease: the yeast connection?
Jean Frederic Colombel et al.
GUT (2013)
Increased levels of circulating Th17 cells in quiescent versus active Crohn's disease
Anders Dige et al.
JOURNAL OF CROHNS & COLITIS (2013)
Which Antipsoriatic Drug Has the Fastest Onset of Action?: Systematic Review on the Rapidity of the Onset of Action
Alexander Nast et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Th17 cells and IL-17 A-Focus on immunopathogenesis and immunotherapeutics
Wim B. van den Berg et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2013)
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study
P. Rich et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber et al.
GUT (2012)
Brodalumab, an Anti-Interleukin-17-Receptor Antibody for Psoriasis
Kim A. Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
Craig Leonardi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Guidelines of care for the management of psoriasis and psoriatic arthritis
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Anne Puel et al.
SCIENCE (2011)
Mechanisms of Disease: Psoriasis.
Frank O. Nestle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
分享论文
